Xspray - INITIATION - Crystal Clear
Xspray Pharma develops generic & improved versions of already marketed drugs that could potentially launch on a semi-exclusive basis to compete against branded therapeutics. The company’s unique RightSize™ technology reformulates branded drugs into an amorphous form, to circumvent secondary patents and thus launch their products before those patents expire. Given that generic companies typically wait until both primary and secondary patents have expired before launching, this strategy creates a window of opportunity where Xspray is the sole competitor to the original drug in a multi-billion-dollar market.For access to the full note, please contact Naresh Chouhan ( )
Provided by our team of experienced analysts, our work is idea driven, based on independence of thought, sector expertise, and firmly focussed on fundamentals and valuation.
New Street Research is an independent, partner-owned, research firm specialising in equity and debt research. Our equity research embraces the following sectors:
- Pan European Telecom Services and Cable
- US Telecoms, Cable, Satellite and Towers
- Global Emerging Market Telecoms
- Japan Telecoms
- Asian Internet
- Pan European Healthcare
- Global healthcare thematic research
We provide debt research on:
- Pan European Telecom Services and Cable
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.